{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:22:39Z","timestamp":1790421759283,"version":"4.1.0"},"reference-count":50,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>(1) Background: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy provide survival benefits to selected patients. We aimed to report our experience and the evolution of our peritoneal surface malignancy program. (2) Methods: From June 2005 to June 2017, 399 patients who underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy at the T\u00fcbingen University Hospital were analyzed from a prospectively collected database. (3) Results: Peritoneal metastasis from colorectal cancer was the leading indication (group 1: 28%; group 2: 32%). The median PCI was 15.5 (range, 1\u201339) in group 1 and 11 (range, 1\u201339) in group 2 (p = 0.002). Regarding the completeness of cytoreduction (CC), a score of 0 was achieved in 63% vs. 69% for group 1 and 2, respectively (p = 0.010). Median overall survival rates for patients in group 1 and 2 for colon cancer, ovarian cancer, gastric cancer and appendix cancer were 34 and 25 months; 45 months and not reached; 30 and 16 months; 39 months and not reached, respectively. The occurrence of grade-III and -IV complications slightly differed between groups (14.5% vs. 15.6%). No 30-day mortality occurred. (4) Conclusions: Specialized centers are able to provide low-morbidity cytoreductive surgery and hyperthermic intraperitoneal chemotherapy without mortality. Strict patient selection during the time period significantly improved CC scores.<\/jats:p>","DOI":"10.3390\/cancers13102471","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T12:58:07Z","timestamp":1621429087000},"page":"2471","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Twelve-Year Single Center Experience Shows Safe Implementation of Developed Peritoneal Surface Malignancy Treatment Protocols for Gastrointestinal and Gynecological Primary Tumors"],"prefix":"10.3390","volume":"13","author":[{"given":"Philipp","family":"Horvath","sequence":"first","affiliation":[{"name":"Comprehensive Cancer Center, Department of General, Visceral and Transplant Surgery, University of T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9720-8243","authenticated-orcid":false,"given":"Can","family":"Yurttas","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Department of General, Visceral and Transplant Surgery, University of T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Beckert","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Department of General, Visceral and Transplant Surgery, University of T\u00fcbingen, 72076 T\u00fcbingen, Germany"},{"name":"Department of General and Visceral Surgery, Schwarzwald-Baar Klinikum, 78052 Villingen-Schwenningen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"K\u00f6nigsrainer","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Department of General, Visceral and Transplant Surgery, University of T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingmar","family":"K\u00f6nigsrainer","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, Department of General, Visceral and Transplant Surgery, University of T\u00fcbingen, 72076 T\u00fcbingen, Germany"},{"name":"Department of General, Visceral and Thoracic Surgery, Academic Teaching Hospital Feldkirch, Carinagasse 47, 6800 Feldkirch, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","article-title":"Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Elias","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(20)30322-3","article-title":"BIG-RENAPE group: Second-look surgery plus hyper-thermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metas-tases (PROPHYLOCHIP-PRODIGE 15): A randomised, phase 3 study","volume":"21","author":"Goere","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S2468-1253(19)30239-0","article-title":"COLOPEC collaborators group: Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): A multicentre, open-label, randomised trial","volume":"4","author":"Klaver","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ejso.2018.10.542","article-title":"HIPEC with oxaliplatin for colorectal peritoneal metastasis: The end of the road?","volume":"45","author":"Ceelen","year":"2019","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.1016\/S1470-2045(20)30497-6","article-title":"Results from the PROPHYLOCHIP-PRODIGE 15 trial","volume":"21","author":"Tanis","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00384-020-03702-y","article-title":"Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: A systematic review and meta-analysis of comparative studies","volume":"35","author":"Zhang","year":"2020","journal-title":"Int. J. Color. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jviscsurg.2019.06.007","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection for concurrent peritoneal and hepatic metastases of gastrointestinal and gyne-cological primary tumors","volume":"156","author":"Horvath","year":"2019","journal-title":"J. Visc. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1245\/s10434-015-4387-5","article-title":"Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative Study","volume":"22","author":"Souadka","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1245\/s10434-010-1039-7","article-title":"Peritoneal carci-nomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy","volume":"17","author":"Glehen","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1007\/s00268-004-7461-x","article-title":"Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Recurrent Peritoneal Carcinomatosis from Ovarian Cancer","volume":"28","author":"Zanon","year":"2004","journal-title":"World J. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.23553","article-title":"Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer","volume":"113","author":"Naticchioni","year":"2008","journal-title":"Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s00268-007-9146-8","article-title":"Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: Prospective study of 81 patients","volume":"31","author":"Cotte","year":"2007","journal-title":"World J. Surg."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jso.23784","article-title":"Poor outcome after cy-toreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology","volume":"111","author":"Braam","year":"2015","journal-title":"J. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/jso.25379","article-title":"Signet ring cell features with peritoneal carcinomatosis in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are associated with poor overall survival","volume":"119","author":"Solomon","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"\u00dcberr\u00fcck, L., Nadiradze, G., Yurttas, C., K\u00f6nigsrainer, A., K\u00f6nigsrainer, I., and Horvath, P. (2020). In-Hospital Mortality and Complication Rates According to Health Insurance Data in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancies in Germany. Ann. Surg. Oncol., 1\u20138.","DOI":"10.1245\/s10434-020-09301-z"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","article-title":"Peritoneal colorectal carcino-matosis treated with surgery and perioperative intraperitoneal chemotherapy: Retrospective analysis of 523 patients from a multicentric French study","volume":"28","author":"Elias","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann. Surg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","article-title":"Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomato-sis","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"ref_19","first-page":"256","article-title":"Clinical delivery system for intraperitoneal hyperthermic chem-otherapy","volume":"40","author":"Spratt","year":"1980","journal-title":"Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/SLA.0b013e3182436c28","article-title":"Multidimensional analysis of the learning curve for cytoreductive surgery and hyperther-mic intraperitoneal chemotherapy in peritoneal surface malignancies","volume":"255","author":"Kusamura","year":"2012","journal-title":"Ann. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/ans.13280","article-title":"Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis","volume":"87","author":"Huang","year":"2017","journal-title":"ANZ J. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1245\/s10434-019-07957-w","article-title":"Diagnostic Laparoscopy as a Selection Tool for Patients with Colorectal Peritoneal Metastases to Prevent a Non-therapeutic Laparotomy During Cytoreductive Surgery","volume":"27","author":"Hentzen","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/bjs.8908","article-title":"Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis","volume":"100","author":"Iversen","year":"2012","journal-title":"BJS"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5608","DOI":"10.1002\/cncr.25356","article-title":"Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intra-peritoneal chemotherapy: A multi-institutional study of 1290 patients","volume":"116","author":"Glehen","year":"2010","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/SLA.0b013e31825704e3","article-title":"Identification of a Subgroup of Patients at Highest Risk for Complications after Surgical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy","volume":"256","author":"Baratti","year":"2012","journal-title":"Ann. Surg."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","article-title":"Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: A French multicentre retrospective cohort study of 566 patients","volume":"39","author":"Bakrin","year":"2013","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_28","first-page":"5689","article-title":"Short-term outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Preliminary analysis of a multicentre study","volume":"34","author":"Arcoraci","year":"2014","journal-title":"Anticancer. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1245\/s10434-009-0875-9","article-title":"Critical Assessment of Risk Factors for Complications After Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei","volume":"17","author":"Saxena","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial","volume":"18","author":"Yang","year":"2011","journal-title":"Ann. Surg. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.18.01688","article-title":"FREGAT and BIG-RENAPE Networks. Cytoreductive Surgery with or without Hyperther-mic Intraperitoneal Chemotherapy for Gastric Cancer with Peritoneal Metastases (CYTO-CHIP Study): A Propensity Score Analysis","volume":"37","author":"Bonnot","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0959-8049(01)00058-2","article-title":"Extensive cy-toreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin","volume":"37","author":"Witkamp","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1245\/s10434-009-0523-4","article-title":"Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C","volume":"16","author":"Lambert","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1245\/s10434-020-09165-3","article-title":"Perioperative and Oncological Outcomes of Combined Hepatec-tomy with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Metastatic Colorectal Cancer","volume":"28","author":"Adileh","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.suc.2017.01.013","article-title":"Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colo-rectal Peritoneal Metastasis","volume":"97","author":"Hall","year":"2017","journal-title":"Surg. Clin. N. Am."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S1470-2045(16)30500-9","article-title":"Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database","volume":"17","author":"Franko","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/SLA.0000000000002899","article-title":"Mutations of RAS\/RAF Pro-to-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin","volume":"268","author":"Schneider","year":"2018","journal-title":"Ann Surg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1245\/s10434-019-07378-9","article-title":"RAS Mutation Decreases Overall Sur-vival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Me-tastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score","volume":"26","author":"Baratti","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jss.2019.02.050","article-title":"RAS Mutation Status Confers Prognostic Relevance in Patients Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer","volume":"240","author":"Morgan","year":"2019","journal-title":"J. Surg. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1245\/s10434-020-09161-7","article-title":"Prog-nostic Impact of Primary Side and RAS\/RAF Mutations in a Surgical Series of Colorectal Cancer with Peritoneal Metastases","volume":"28","author":"Baratti","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1245\/s10434-019-07452-2","article-title":"Prognostic Impact of BRAF and KRAS Muta-tion in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC","volume":"27","author":"Graf","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10120-019-00978-0","article-title":"Peritoneum Surface Oncology Group and members of the StuDoQ|Peritoneum Registry of the German Society for General and Visceral Surgery (DGAV). Peritoneal metastasis in gastric cancer: Results from the German database","volume":"23","author":"Rau","year":"2020","journal-title":"Gastric Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1245\/s10434-014-4157-9","article-title":"Cytoreductive Surgery and HIPEC in Recurrent Epithelial Ovarian Cancer: A Prospective Randomized Phase III Study","volume":"22","author":"Spiliotis","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ygyno.2012.09.020","article-title":"Cytoreductive sur-gery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: A case-control study on survival in patients with two year follow-up","volume":"127","author":"Fagotti","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer","volume":"378","author":"Koole","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ejso.2018.10.528","article-title":"Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemo-therapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis","volume":"45","author":"Wang","year":"2019","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/02656736.2019.1612101","article-title":"Efficacy of hyperthermic intraperitoneal chemotherapy in patients with epithelial ovarian cancer: A meta-analysis","volume":"36","author":"Wu","year":"2019","journal-title":"Int. J. Hyperth."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e18355","DOI":"10.1097\/MD.0000000000018355","article-title":"Selection of patients with ovarian cancer who may show survival benefit from hyperthermic intraperitoneal chemotherapy: A system-atic review and meta-analysis","volume":"98","author":"Kim","year":"2019","journal-title":"Medicine"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.21037\/gs-20-335","article-title":"Hyperthermic intraper-itoneal chemotherapy (HIPEC) for ovarian cancer recurrence: Systematic review and meta-analysis","volume":"9","author":"Cianci","year":"2020","journal-title":"Gland Surg."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/10\/2471\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:03:56Z","timestamp":1760162636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/10\/2471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["cancers13102471"],"URL":"https:\/\/doi.org\/10.3390\/cancers13102471","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]}}}